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Background: Activation of the mTOR pathway has been implicated in the development of several
malignancies and alterations in TSC1, TSC2, STK11 and NF1, can lead to the dysregulation of this pathway.
Furthermore, mutations in TSC1 and NF2 are known to confer sensitivity to everolimus—an mTOR
inhibitor. Based on these data, a single-arm, open label, single-institution phase II basket study was designed
to assess the activity of everolimus in patients with solid malignancies whose tumors harbored mutations in
TSC1, TSC2, NF1, NF2, or STK11.
Methods: A total of 12 patients with histologically confirmed diagnosis of advanced solid tumors
(metastatic, recurrent, or unresectable) with mutations in TSC1, TSC2, NF1, NF2 or STK11 genes, who
had failed at least one line of standard of care systemic therapy, were enrolled to this open label, single-arm
study. Presence of mutations in TSC1, TSC2, NF1, NF2 or STK11 genes was assessed using targeted-next
generation sequencing (NGS). All eligible patients were treated with everolimus at an initial dose of 10 mg
orally once daily in cycles of 28 days. The primary endpoint of this study was overall response rate (ORR).
Results: Of 12 patients enrolled, 8 were evaluable for response at the end of 2 cycles. One complete
response (CR) was observed (12.5%) and one patient (12.5%) had stable disease (SD), while six (75%)
patients showed disease progression. Everolimus was overall well tolerated with anemia, decreased neutrophil
and lymphocyte counts, peripheral edema and hyperglycemia representing the most common adverse events.
One patient discontinued treatment due to a treatment related grade 4 pericardial effusion. Both patients
with CR or SD had a diagnosis of lung adenocarcinoma with NF1 or STK11 mutations, respectively.
Conclusions: Although this study failed to meet its prespecified ORR threshold for success of 30%
or higher, exploratory analyses suggest potential activity for everolimus in a subset of patients with lung
adenocarcinomas with STK11 or NF1 mutations. Further studies are necessary to systematically explore the
clinical activity of everolimus, potentially as a combination therapy, in these patients.
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Introduction
Mammalian target of rapamycin (mTOR) is a key protein
kinase that regulates cell growth, proliferation and
survival (1). Activation of the mTOR pathway has been
implicated in the development of several malignancies
(2,3). This protein kinase is mainly activated via the PI3K
pathway through AKT and the tuberous sclerosis complex
(TSC1/TSC2) (1). This pathway is also regulated by
tumor suppressors such as STK11 and NF1, which are
frequently altered across different cancers (4,5). STK11,
also known as LKB1, activates mTOR through activation
of AMPK and phosphorylation of TSC2, whereas NF1
prevents the downstream activation of the mTOR pathway
by terminating the active state of RAS proteins (4,5).
Mutations in TSC1, TSC2, STK11 and NF1 genes can lead
to mTOR pathway dysregulation and promote tumor cell
growth (6). Inhibiting mTOR could therefore represent
an approach to treat solid tumors that harbor mutations in
tumor suppressors such as STK11, NF1, TSC1 and TSC2.
Inhibitors of the mTOR pathway have demonstrated
activity in different human solid tumor cell lines and in
mouse xenograft models (7-10). Everolimus is an mTOR
inhibitor that was first approved in 2009 by the the U.S.
Food and Drug Administration (FDA) for the treatment
of patients with advanced renal cell carcinoma (RCC) (11).
Thereafter, approvals for everolimus for the treatment of
different solid tumors were granted including subependymal
giant cell astrocytoma, advanced hormone receptor positive
HER-2 negative breast cancer, advanced pancreatic
neuroendocrine and GI cancers and lung cancers, renal cell
carcinoma, renal angiomyolipoma and tuberous sclerosis
complex (12). Similarly other mTOR inhibitors such as
temsirolimus, have also been studied in multiple cancers,
and temsirolimus is currently approved in patients with
renal cell carcinoma (13). Nevertheless, despite showing
promising activity in preclinical studies across a variety of
different cancers known to upregulate mTOR signaling,
drugs such as everolimus and temsirolimus have failed to
demonstrate significant efficacy in clinical trials—possibly
owing to the lack of strong biomarkers that predict for
responsiveness to mTOR inhibition (14).
In an attempt to identify predictors of response to
everolimus, Iyer et al. performed whole genome sequencing
(WGS) on tumoral DNA from a patient with metastatic
bladder cancer that achieved complete response while on
everolimus, and identified a two-base-pair deletion in the
TSC1 gene and a nonsense mutation in the NF2 gene (15).
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Additional analyses by Iyer and colleagues also found a
longer duration of response with everolimus in patients
whose tumors harbored TSC1 mutations, compared to
patients with wild type (WT) (15). Additionally, findings
from other groups suggest a role for mTOR inhibition in
malignant peripheral nerve sheath tumors (MPNSTs) with
NF1 mutation, and breast cancer with STK11 mutation
(16,17). Based on these observations, we designed a phase
II basket study to examine the activity of mTOR inhibition
in patients with solid tumors containing TSC1, TSC2,
NF1, NF2, or STK11 mutations. Everolimus was selected
as the mTOR inhibitor of choice for this study given its
relatively well tolerated toxicity profile and ease of oral
administration.
We present the following article in accordance with the
TREND reporting checklist (available at https://dx.doi.
org/10.21037/jtd-21-195).
Methods
Study design
This was a single-arm, open label, single-institution phase
II basket study of everolimus in patients with advanced solid
tumors (ClinicalTrials.gov identifier NCT02352844) conducted
at the outpatient oncology clinics at Washington University
School of Medicine and Alvin J. Siteman Cancer Center in St.
Louis, MO. The study was conducted in accordance with the
Declaration of Helsinki (as revised in 2013). This study was
reviewed and approved by the Washington University Human
Research Protection Office institutional review board (IRB ID
# 201502067). All patients provided written informed consent
for participation in this study.
Eligibility
Adults (age ≥18 years) with histologically confirmed
diagnosis of advanced solid tumor (metastatic, recurrent or
unresectable) with mutations in TSC1, TSC2, NF1, NF2 or
STK11 genes, who had failed at least one line of standard of
care systemic therapy were eligible. Patients needed to have
a 2 week washout between the last line of antineoplastic
therapy and initiation of everolimus. There was no limit to
the number of prior treatments patients could have received
prior to enrollment. Further eligibility criteria included
adequate bone marrow function (leukocytes >3,000/mcl,
ANC >1,500/mcL, platelets >100,000 and hemoglobin
>9.0 g/dL), hepatic function (total serum bilirubin ≥2.0×
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normal limit and AST/ALT ≤2.5× normal limit), and renal
function (serum creatinine ≤1.5× normal limit or creatinine
clearance 45mL/min), fasting cholesterol ≤300 mg/dL
and fasting triglycerides ≤2.5× normal limit. Patients
were required to have an ECOG performance status of
0–2. Patients with symptomatic brain metastases and
those on chronic treatment with corticosteroids, or other
immunosuppressive agents, were excluded.
Mutations in TSC1, TSC2, NF1, NF2 or STK11 genes
were assessed using in-house and/or commercially available
targeted-next generation sequencing (NGS) assays that
utilized DNA extracted from formalin fixed paraffin
embedded (FFPE) tissue blocks as part of their standard of
care treatment (18). Patients with circulating tumor DNA
(ctDNA) test results demonstrating mutations in these
genes were also eligible for enrollment (19).
Treatment procedures
All eligible patients were treated with everolimus at an
initial dose of 10 mg orally daily as a take-home medication
in cycles of 28 days. Treatment with everolimus was
continued until disease progression or unacceptable toxicity,
whichever occurred first. Everolimus-related toxicities were
managed with temporary dose delays or subsequent dose
reductions. Dose reductions of 50% were implemented
for recurrent grade 2 stomatitis, grade 3 hyperlipidemia
or grade 3 hyperglycemia, and for grade 2 non-infectious
pneumonitis. The study drug was discontinued if more than
two dose reductions (50% and then 75%) were required due
to toxicities. The use of live vaccinations was not permitted
within a week of starting study treatment and during
the study.
Efficacy and safety
Patients were evaluated clinically and by laboratory
assessment with every cycle of everolimus in the outpatient
clinic (every 4 weeks). Baseline scans were followed by
repeat imaging with computed tomography (CT) scans
obtained every 8 weeks (2 cycles) to evaluate response to
treatment. Tumor response and progression were defined
by the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 (20). The duration of overall response
was defined as the time from when the measurement
criteria for complete response (CR) or partial response
(PR), were first met, until the time at which recurrent or
progressive disease was objectively documented. Duration
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of stable disease (SD) was similarly defined. Patients who
discontinued study therapy prior to the first radiological
exam were not considered evaluable for response, but were
still considered evaluable for toxicity. Adverse events (AEs)
were recorded and graded according to the National Cancer
Institute Common Terminology Criteria version 4.0 (21).
Outcomes
The primary end point of this study was overall response
rate (ORR). Secondary end points included an examination
of the correlation between presence of different mutations
in the mTOR pathway and response to everolimus, and
investigation of the genetic changes associated with disease
progression following initial response to everolimus.
Statistical analysis
The study was designed to assess the response rate of
everolimus in solid tumors that harbor TSC1, TSC2,
NF1, NF2 and STK11 mutations. Since this was a study in
patients with specifically targeted mutations, a substantial
treatment effect size was expected. Based on historical
data, we assumed a null hypothesis of an ORR of <1% in
this setting. We hypothesized that an overall response rate
of 30% or higher would warrant further investigation.
Assuming a dropout rate near to zero, a target accrual of
12 patients was planned for this study, based on the exact
single-stage design with 85% power at a 1-sided 0.05
significance level (using ph2single function from library
clinfun in the R package) (22,23).
All data including demographic and clinical
characteristics of enrolled patients, and response and
toxicity by grade were summarized using descriptive
statistics, i.e., statistics for continuous variables included
medians and ranges, and statistics for qualitative variables
included counts and percentages. Waterfall plot was
graphed to visualize tumor responses in terms of percent
change of tumor size from baseline.
Results
Patient characteristics
Between February 2016 and June 2017, 12 patients with
advanced solid malignancies were enrolled to this study.
Patient characteristics are listed in Table 1. The majority
of patients had a diagnosis of non-small cell lung cancer
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Table 1 Patients characteristics
Characteristic
Median age [range] (years)

Previously treated cancer
harboring TSC1, TSC2, NF1 ,
NF2, STK11 mutation.

Data
66 [40–86]

Sex, n (%)
Female

7 (58.3)

Male

5 (41.7)

Screen failures
n=5

Unknown or not reported

Evaluable n=8

11 (91.7)

Complete Response n=1
Adenocarcinoma of the lung
(STK11 c.375-2del and
c.375-G>C)

1 (8.3)

Prior therapy lines [range]
Median

4 Subjects discontinued
treatment prior to first
scheduled scan

Enrolled n=12

Race, n (%)
White

Unevaluable
n=4

Stable Disease n=1
Adenocarcinoma of the lung
(NF1 p.Y489C)

3 [1–5]

Tumor type, n (%)
Adenocarcinoma of the lung

5 (42)

NSCLC, NOS

1 (8.3)

Carcinoma of unknown primary

2 (17)

Gallbladder cancer

1 (8.3)

Cervical adenocarcinoma

1 (8.3)

Pancreatic adenocarcinoma

1 (8.3)

Small cell lung cancer

1 (8.3)

Progressive Disease n=6
Gallbladder Adenocarcinoma
Pancreatic Adenocarcinoma
NSCLC NOS
Adenocarcinoma of the lung
Endocervical Adenocarcinoma

Figure 1 CONSORT diagram.

(NSCLC) (6/12; 50%), followed by carcinoma of unknown
primary site (2/12;17%), small cell lung cancer (1/12; 8.3%),
gall bladder adenocarcinoma (1/12; 8.3%), pancreatic
adenocarcinoma (1/12; 8.3%) and cervical cancer (1/12;
8.3%). Seven patients (58%) were female, and eleven (92%)
were Caucasian. The median age of patients enrolled to
the trial was 66 years (range, 40–86 years). With regard to
evaluable patients (8/12; 75%), four patients had STK11
mutations and four harbored mutations in NF1.

provider. The median number of cycles administered
was 2 across the cohort of evaluable patients. Among the
eight evaluable patients, one complete response (CR)
was observed in a patient with non-small cell lung cancer
representing a response rate of 12.5%. This patient only
received treatment with everolimus for 2 weeks, before
discontinuation due to treatment-related toxicities including
grade 3 hyponatremia and a grade 4 pericardial effusion.
However, follow-up assessment at 10 week mark showed a
complete response that was durable and lasted more than
10 months. One patient with metastatic NSCLC (12.5%)
demonstrated SD and 6 (75%) had disease progression
(Figure 1) on the first post-treatment scan. The patient
with SD was on therapy for 6 cycles before discontinuing
treatment for progression. Notably, in this small cohort,
disease control (CR, PR and SD) was observed in 2 of the
5 patients with lung adenocarcinoma.

Antitumor activity

Safety

Four patients were not evaluable for response due to study
withdrawal prior to first evaluation. Three of these four
patients were lost to follow-up and one patient withdrew
from study after 2 weeks at the discretion of the treating

Table 2 summarizes grade 2 and higher treatment-related
toxicities. Twelve patients that received everolimus were
evaluable for toxicity. Overall, treatment with everolimus
was well tolerated and no new toxicities were observed.

Mutations identified, n (%)
STK11

7 (58.3)

NF1

5 (41.7)

ITT, intent-to-treat; NSCLC, non-small lung cancer; NOS, not
otherwise specified.
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Table 2 Adverse events (N=12)
Toxicity

Grade 2 [%]

Grade 3 [%]

Grade 4 [%]

Total [%]

Alkaline phosphatase increased

1 [8]

0

0

1 [8]

Anemia

5 [42]

0

0

5 [42]

Anorexia

1 [8]

0

0

1 [8]

Atrial fibrillation

1 [8]

0

0

1 [8]

0

1 [8]

0

1 [8]

Cough

1 [8]

0

0

1 [8]

Dizziness

1 [8]

0

0

1 [8]

Dyspnea

1 [8]

0

0

1 [8]

Edema limbs

2 [17]

0

0

2 [17]

Fatigue

1 [8]

1 [8]

0

2 [17]

Hyperglycemia

0

2 [17]

0

2 [17]

Hyperkalemia

1 [8]

0

0

1 [8]

Hypertension

0

1 [8]

0

1 [8]

1 [8]

0

0

1 [8]

Hyponatremia

0

1 [8]

0

1 [8]

Lymphocyte count decreased

0

3 [25]

0

3 [25]

1 [8]

1 [8]

0

2 [17]

0

1 [8]

0

1 [8]

Neutrophil count decreased

2 [17]

0

0

2 [17]

Non-cardiac chest pain

1 [8]

0

0

1 [8]

0

0

1 [8]

1 [8]

Platelet count decreased

1 [8]

0

0

1 [8]

Pleural effusion

2 [17]

0

0

2 [17]

Rash maculo-papular

1 [8]

0

0

1 [8]

White blood cell decreased

1 [8]

1 [8]

0

2 [17]

Blood bilirubin increased

Hypoalbuminemia

Mucositis oral
Nausea

Pericardial effusion

Grade 2 toxicities observed in greater than 10% patients
included anemia in 5 patients (42%), peripheral edema in
2 patients (17%), neutrophil decrease in 2 patients (17%),
and pleural effusion in 2 patients (17%). Grade 3 toxicities
included lymphopenia in 3 patients (25%), hyperglycemia
in 2 patients (17%), followed by fatigue, increased blood
bilirubin, hypertension, hyponatremia, oral mucositis,
nausea, and low white blood cell count in 1 patient each
(8% each). Grade 4 pericardial effusions were observed in
2 patients on study. However, only one of these events was
assessed as being related to everolimus and led to treatment
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discontinuation.
Molecular characteristics
Of the patients who were evaluable for a response, 50%
(n=4) of the patients had tumors with NF1 mutations and
50% (n=4) had tumors with STK11 mutations (Table 3).
None of the alterations in NF1 or STK11 were recurrent.
Mutations observed in NF1 were missense (n=3) and
nonsense (n=1), and STK11 mutations were mostly
nonsense (n=2). The single patient with a CR had two
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Table 3 Patient disease molecular characteristics
Cancer type

Duration of
treatment (cycles)

Best
Reason for
tesponse tiscontinuation

Mutation of
interest

RAS pathway
Other mutated genes
mutation

Non-small cell lung
cancer (NOS)

2

PD

Disease progression

NF1 p. E8*

N/A

BRCA1, CDH1

Adenocarcinoma of the
gallbladder

2

PD

Disease progression

STK11 p.E199*

N/A

ATM, ERCC2, GNAS,
MAP3XK1, UGT1A7

Adenocarcinoma of the
lung

2

PD

Pericardial effusion
NF1 R1038T
(unrelated to treatment)

HRAS E91Q¥

NFE2L2, TP53,
CDH1, RIT1, EGFR
G719A (¥)

Adenocarcinoma of the
lung

1

CR

Pericardial effusion
(related to treatment)

STK11 c.375-2del N/A
and c.375-G>C

SMAD4, BRCA2

Adenocarcinoma of the
pancreas

1

PD

Disease progression

NF1 c.7190C>T
and c.7253C>T

KRAS G12D

CDKN2A, TP53,
SMAD4, CSF1R

Adenocarcinoma of the
lung

6

SD

Disease progression

NF1 p.Y489C

N/A

MAP2K2, TP53

Adenocarcinoma of the
lung

2

PD

Disease progression

STK11 Exon 1
E33X

KRAS G12C

TP53

Adenocarcinoma of the
endocervix

2

PD

Disease progression

STK11 L282fs*5

KRAS G12C

CDKN2A

¥

, identified through plasma genotyping (circulating tumor DNA). NOS, not otherwise specified; SD, stable disease; CR, complete
response; PD, progression of disease; N/A, not applicable.

noncoding variants in cis in the STK11 gene, with one of
the alterations occurring at a canonical splice acceptor site
of the second intron, and the second occurring upstream of
this splice site acceptor site. Tumor from the patient with
SD demonstrated a missense mutation in NF1.
Discussion
This phase II study explored the response rate to
everolimus in a heavily pre-treated population of patients
with solid tumors with mutations in tumor suppressor
genes that regulate the mTOR pathway. Overall, this
study failed to demonstrate significant single agent activity
with everolimus in solid tumors with mutations in NF1,
NF2, TSC1, TSC2, and STK11. Nevertheless, our findings
suggest that everolimus may be active in a subset of
patients including those with adenocarcinoma of the lung.
Two of four evaluable patients with lung adenocarcinoma
demonstrated disease control with everolimus in our cohort.
It is possible that the lack of activity with everolimus in
other tumor types included in our study could be a result of
differences in tumor biology associated with site of origin.
Such differential responses to targeted therapies based on
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tissue of origin have previously been reported in the context
of BRAF and KRAS inhibitors (24-26). For instance, while
inhibitors targeting the BRAF V600E mutation or KRAS
G12C mutation have demonstrated considerable activity
in melanoma (24) and lung cancers (25), respectively, these
drugs have failed to demonstrate significant single agent
activity in patients with colorectal cancer (26).
Alternatively, the lack of efficacy with everolimus
in this study, could also be related to the effect of cooccurring genomic alterations in tumor samples. Patients
that derived benefit from everolimus in our study had
lung adenocarcinomas that contained NF1 and STK11
mutations, while lacking mutations in the RAS pathway
(such as KRAS and HRAS). On the contrary, the lung
adenocarcinoma patients whose disease failed to respond
to treatment, demonstrated combined alteration of KRAS
and STK11 or NF1 and HRAS. Furthermore, two other
patients with non-lung malignancies who failed to respond
to treatment, also had tumors with co-existing KRAS
mutations, raising the possibility that co-occurring KRAS
mutations could predict for resistance to everolimus in this
patient population (Table 3). Such a hypothesis would be
supported by observations from pre-clinical studies in which
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60%
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PD: ≥+20%
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Data Sharing Statement: Available at https://dx.doi.
org/10.21037/jtd-21-195
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CR
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Patient lD
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Figure 2 Waterfall plot (N=8).

the presence of KRAS mutations has been shown to predict
for resistance to mTOR inhibition in PIK3CA mutated
cancer cell lines and xenografts (27). In this study, Di
Nicolantonio et al. observed that colorectal cancer cell lines
carrying PIK3CA mutations were responsive to everolimus,
except when KRAS mutations occurred concomitantly (27).
Furthermore, when they performed genetic analysis of
tumors from patients with different solid tumors (mostly
colorectal and breast cancer) that were treated with
everolimus, patients whose tumors carried PIK3CA and
KRAS mutations displayed lack of clinical benefit from
everolimus (27). Finally, the functional significance of the
specific mutations affecting genes of interest in our study
was not always clear—particularly in samples that contained
missense mutations. It is possible that some of the variants
observed in this study were passenger mutations that did
not lead to activation of mTOR signaling.
Overall, our findings suggest that patients with
adenocarcinoma of the lung with NF1 or STK11 mutations
without co-occurring mutations in KRAS or HRAS genes
may derive some benefit from everolimus (Figure 2). STK11
and NF1 mutations are frequently seen in lung cancer
(17.4% and 11.7%, respectively) (28,29). Nevertheless, these
observations should be viewed as hypothesis generating and
will require further validation in larger studies. Additional
pre-clinical studies exploring genomic features that predict
for response to everolimus in lung adenocarcinoma will also
be necessary to inform the design of future studies.
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